Table 1.

Description of the characteristics and outcome of the patients with AML based on the levels of FLT3–ITD. A total of 2901 adult patients who enrolled in the consecutive multicenter AML PETHEMA trials and were included in the PETHEMA registry were evaluated. We separated FLT3–ITD ARs into 4 increasing intervals according to a previous study in order to facilitate the understanding of the results. Abbreviations: ECOG, Eastern Cooperative Oncology Group status performance; WBC, white blood cell; cytogenetic risk based on MRC classification; OS, overall survival; RFS, relapse-free survival.

Variable	FLT3 DIT NO DETECTED	FLT3 RATIO < 0.25	FLT3 RATIO 0.251–0.50	FLT3 RATIO 0.51–0.80	FLT3 RATIO > 0.80	Significance
Age at diagnosis
Mean	53.6	53.1	53.8	53.11	52.9	p = NS
Range	12.3–81.2	19.9–76.8	17.7–75.6	17.1–77.6	13.8–81
Sexo
Female	1043	36	44	56	90	p = 0.008
Male	1278	39	38	48	67
ECOG
0	833	26	37	41	35	p = 0.006
1	838	29	25	26	70
2	240	11	7	18	22
3	49	1	4	5	6
4	14	0	0	1	2
WBC count (×1000/mL)
Mean	28.28	48.86	49.46	92.5	101.06	p < 0.001
Range	0.6–340	0.7–365	0.31–298	1.7–347	1.4–434
Cytogenetic Risk
Low Risk	228	2	3	1	0	p < 0.001
Intermediate Risk	1314	59	61	76	130
High Risk	535	5	7	9	10
NPM1 mutation
Presence	509	44	45	63	102	p < 0.001
Absence	1592	29	33	34	49
OUTCOME	FLT3 DIT NO DETECTED	FLT3 RATIO < 0.25	FLT3 RATIO 0.251–0.50	FLT3 RATIO 0.51–0.80	FLT3 RATIO > 0.80	Significance
Complete Remission, % (n)	71 (1539)	69 (52)	75 (61)	55 (57)	63 (99)	p = 0.057
Resistance Disease, % (n)	22 (240)	20 (15)	15 (12)	29 (29)	27 (43)	p = NS
Early Death, % (n)	7 (64)	11 (8)	10 (8)	16 (17)	10 (15)	p = NS
Relapse Disease, % (n)	35 (801)	27 (20)	37 (30)	27 (28)	40 (63)	p = NS
OS (median, CI), months	20.4 (18.0–22.7)	18.6 (9.8–27.5)	14.8 (12.8–16.8)	13.5 (7.8–19.3)	11.0 (8.9–13.5)	p < 0.001
RFS (median, CI), months	34.1 (22.3–45.9)	32.7 (13.1–52.2)	22.9 (0–46.3)	90.7 (5.3–176)	32.4 (24–40.7)	p < 0.001